PK-MED
26.2.2024 09:01:55 CET | Business Wire | Press release
PK MED, a biotechnology company developing injectable smart implants for drug release in rheumatology and cell homing for bone marrow transplantation, today announced a significant potential breakthrough in the fight against gout, a form of arthritis that is widespread throughout the world. During a Type B pre-IND meeting1, the Food and Drug Administration gave its clearance to directly initiate the clinical program for PKM-01 with a phase 2 trial for gout patients, without undertaking phase 1 studies. PKM-01 is a local intra-articular injection treatment for gout flares, developed by PK MED, aiming to provide a fast an effective pain relief and powerful and safe anti-inflammatory effect. Thanks to its low-risk toxicity profile, PKM-01's clinical program will start directly in phase 2, which should considerably speed up time-to-market.
Gout is characterized by repeated intense inflammatory acute episodes and excruciating pain, called gout flares, due to deposits of uric acid microcrystals in the joints (e.g. knee, ankle, foot…). This most common form of acute arthritis affects more than 10 million patients in the United States and is increasingly prevalent worldwide due to an aging population, changing lifestyles, diet and obesity. Oral colchicine is a reference anti-inflammatory treatment, however, only a low daily dose can be used due to its significant systemic exposure and severe potential toxicity. Furthermore, its delayed effect on inflammation relieves only partially, and typically not before one day, the excruciating pain resulting from an inflamed joint.
PKM-01, an innovative intra-articular injectable treatment candidate for gout flares, is a combination of a controlled release colchicine, with an anesthetic molecule, ropivacaine. In contrast to the existing treatments, the anesthetic effect of ropivacaine is expected to act on pain within minutes after injection in the affected joint. In addition, the high and sustained local colchicine concentration is anticipated to provide a powerful and long-lasting effect on inflammation and pain without systemic exposure and toxicity. This dual-action approach is expected to provide immediate and prolonged pain relief induced by gout flares, an effective treatment of inflammation, while providing a favorable safety profile.
The phase 2 trial, a dose range study assessing three doses of PKM-01 in a prospective, randomized trial, will evaluate safety, pain relief and effect on inflammation, to select the PKM-01 optimal dose for the pivotal phase 3 trial.
The market targeted by PKM-01 is considerable, with annual sales estimated, depending on indication and pricing, at over $1 billion in the US alone, driven by a strong unmet medical need, and a high and rising prevalence of gout worldwide.
Prof. Angelo Gaffo, head of the rheumatology section specializing in microcrystalline arthritis at the VA Hospital in Birmingham, Alabama, USA, says: "This product will fill a very important gap in the treatment of gout attacks: an effective and safe alternative for all patients and for those with contraindications to other therapies. As the gout population ages and diversifies, there are more and more patients with contraindications, and there are no good alternatives for them."
Gauthier Pouliquen, Ph.D., CEO of PK MED, comments: "This FDA feedback is excellent news for clinicians and patients suffering from gout flares. It should significantly accelerate the time-to-market for PKM-01. PK MED is now entering the fund-raising phase to finance PKM-01 phase 2 clinical trials. With a robust patent protection and a clear path to deliver phase 2 results, PKM-01 represents an attractive and low-risk opportunity for investors and partners."
About PK MED
PK MED is a French biotechnology company, founded in 2019 by Truffle Capital, developing injectable smart implants for drug release in rheumatology and cell homing for bone marrow transplantation. PK MED's unique expertise and technological know-how enable evolving existing systemic treatments into new, safer and more effective patented local therapies.
PK MED has developed a portfolio of projects in indications where medical needs are high, starting with gout (PKM-01) and Hematopoietic Stem Cells transplants (PKM-02).
____________________________
1 Type B Meetings (fda.gov)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240225280244/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release
Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release
Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release
Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release
The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release
Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
